Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIRNASDAQ:CRVSNASDAQ:IMMPNASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.16-1.6%$2.91$2.46▼$4.15$270.43M0.18316,296 shs340,714 shsCRVSCorvus Pharmaceuticals$4.19-1.2%$3.60$1.75▼$10.00$285.63M0.57765,603 shs763,117 shsIMMPImmutep$1.74+0.6%$1.78$1.32▼$2.80$254.11M1.76208,701 shs46,848 shsMNOVMediciNova$1.33-3.6%$1.43$1.12▼$2.55$65.23M0.4237,627 shs3,017 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-1.56%-0.63%+23.92%+2.60%-16.40%CRVSCorvus Pharmaceuticals-1.18%+7.16%+15.75%-7.30%+102.42%IMMPImmutep+0.58%-6.45%-4.92%-2.25%-32.03%MNOVMediciNova-3.62%-5.67%-2.92%-14.19%-1.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals3.3454 of 5 stars3.34.00.00.02.72.51.3CRVSCorvus Pharmaceuticals2.8429 of 5 stars3.52.00.00.03.32.50.6IMMPImmutep1.3419 of 5 stars3.51.00.00.02.60.00.0MNOVMediciNova2.1096 of 5 stars3.53.00.00.02.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0089.87% UpsideCRVSCorvus Pharmaceuticals 3.00Buy$15.00258.00% UpsideIMMPImmutep 3.00Buy$7.00302.30% UpsideMNOVMediciNova 3.00Buy$9.00576.69% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, CRVS, AVIR, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.004/9/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.003/26/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/14/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$6.65 per shareN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.79 per shareN/AIMMPImmutep$5.14M49.44N/AN/A$1.05 per share1.66MNOVMediciNova$1M65.23N/AN/A$1.07 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$135.96M-$1.65N/AN/AN/AN/A-34.90%-32.38%8/6/2025 (Estimated)CRVSCorvus Pharmaceuticals-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%8/5/2025 (Estimated)IMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)MNOVMediciNova-$8.56M-$0.23N/AN/AN/AN/A-19.66%-18.63%8/6/2025 (Estimated)Latest MNOV, CRVS, AVIR, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MNOVMediciNova-$0.14-$0.06+$0.08-$0.06N/AN/A5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AIMMPImmutepN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.3319.33CRVSCorvus PharmaceuticalsN/A0.920.92IMMPImmutep0.0118.2518.25MNOVMediciNovaN/A13.8816.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CRVSCorvus Pharmaceuticals46.64%IMMPImmutep2.32%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%CRVSCorvus Pharmaceuticals28.50%IMMPImmutep3.07%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7085.58 million69.43 millionOptionableCRVSCorvus Pharmaceuticals3068.17 million44.15 millionOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableMNOVMediciNova1049.05 million41.74 millionOptionableMNOV, CRVS, AVIR, and IMMP HeadlinesRecent News About These CompaniesStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)May 20, 2025 | marketbeat.comMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025April 14, 2025 | globenewswire.comMediciNova says first patient enrolled in EAP trial to evaluate MN-166April 9, 2025 | markets.businessinsider.comFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) PatientsApril 8, 2025 | globenewswire.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comMediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MNDDecember 5, 2024 | quiverquant.comMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDDecember 5, 2024 | globenewswire.comMediciNova Inc.December 5, 2024 | wsj.comD. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy RecommendationDecember 3, 2024 | msn.comMediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finanznachrichten.deMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finance.yahoo.comMediciNova provides update in letter to stockholdersNovember 20, 2024 | markets.businessinsider.comMediciNova, Inc. Provides Corporate Update and Highlights Ongoing Clinical Trials for MN166 and Other ProgramsNovember 19, 2024 | quiverquant.comMediciNova, Inc. Receives Notice of Allowance for Patent on MN-001 Method to Decrease Triglyceride Synthesis in the LiverNovember 15, 2024 | quiverquant.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New ...November 14, 2024 | bakersfield.comMediciNova granted Notice of Allowance for MN-001 patent by USPTONovember 14, 2024 | markets.businessinsider.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the LiverNovember 14, 2024 | globenewswire.comMediciNova notified of settlement in Sanofi Novartis litigationNovember 12, 2024 | markets.businessinsider.comMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-NovartisNovember 11, 2024 | globenewswire.comMediciNova announces update of Phase 2/3 MN-166 trial at NEALS meetingOctober 24, 2024 | markets.businessinsider.comMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)October 23, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, CRVS, AVIR, and IMMP Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.16 -0.05 (-1.56%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.22 +0.05 (+1.74%) As of 06/13/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Corvus Pharmaceuticals NASDAQ:CRVS$4.19 -0.05 (-1.18%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.23 +0.04 (+0.95%) As of 06/13/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Immutep NASDAQ:IMMP$1.74 +0.01 (+0.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.76 +0.02 (+1.15%) As of 06/13/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.MediciNova NASDAQ:MNOV$1.33 -0.05 (-3.62%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
